Clinical data confirms elimination of requirement for finger-stick calibration, de-risking pathway to commercialization for the company’s next-generation CGM+ biosensor platformDUBLIN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling positive clinical trial results demonstrating a major technical breakthrough and de-risking th ...

Core Insights - Trinity Biotech plc has launched CGM+, a next-generation wearable biosensor platform aimed at the $260 billion AI wearables market, currently in the later stages of development [1][10][12] Product Features - CGM+ integrates a minimally invasive electrochemical glucose sensor with continuous monitoring of heart activity, body temperature, and physical activity, all within a single modular device [2][9] - The device is designed for real-time AI analysis, providing insights into metabolic factors such as sleep, stress, and physical activity [2][10] - The proprietary needle-free glucose sensor technology reduces disposable components and waste, lowering the cost of care compared to existing market products [3][4] Market Positioning - CGM+ is positioned at the intersection of high-growth sectors, targeting both clinical and consumer health markets [12][13] - The product aims to bridge the gap between medical-grade monitoring and consumer wellness insights, establishing Trinity Biotech as a leader in intelligent wearables [2][7] Strategic Outlook - The company anticipates a commercial launch of CGM+ in mid-2026, with multiple revenue streams expected from device sales, AI analytics subscriptions, and partnerships with healthcare providers and insurers [13][14] - CGM+ is seen as a foundational platform for AI-native health applications, supporting both clinical workflows and consumer health optimization [11][10] Industry Growth Projections - The global continuous glucose monitoring market is projected to grow from $13.28 billion in 2025 to $28.72 billion by 2030, with a CAGR of 16.68% [16] - The AI in healthcare market is forecasted to reach approximately $200 billion by 2030, growing at a CAGR of 37.6% [16] - The wearable AI market is expected to surpass $260 billion by 2032, with a CAGR of 27.0% [16]